Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis

Showing results (181-190 of 251) with videos related to

Pageof 26
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal of the National Cancer Institute|February 27, 2009
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancerDimitra Tsavachidou, Timothy J McDonnell, Sijin Wen, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Oncogene|September 2, 2021
P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasisMing Zhu, Ruiqing Peng, Xin Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasesPaul Mathew, Peter F Thall, Corazon D Bucana, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
JCO Oncology Practice|November 7, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone TherapyNeha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone AcetateGerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Oncotarget|November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testisMehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Pageof 26

Showing results (181-190 of 251) with videos related to

Sort By:
Pageof 26
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal of the National Cancer Institute|February 27, 2009
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancerDimitra Tsavachidou, Timothy J McDonnell, Sijin Wen, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Oncogene|September 2, 2021
P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasisMing Zhu, Ruiqing Peng, Xin Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasesPaul Mathew, Peter F Thall, Corazon D Bucana, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
JCO Oncology Practice|November 7, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone TherapyNeha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone AcetateGerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Oncotarget|November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testisMehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Pageof 26